CL2018001432A1 - 5- (5- (2- (3- aminopropoxi) -6-metoxifenilo) -1h-pirazol-3-ylamino) pirazina-2-carbonitrilo (s) -lactato monohidrato - Google Patents
5- (5- (2- (3- aminopropoxi) -6-metoxifenilo) -1h-pirazol-3-ylamino) pirazina-2-carbonitrilo (s) -lactato monohidratoInfo
- Publication number
- CL2018001432A1 CL2018001432A1 CL2018001432A CL2018001432A CL2018001432A1 CL 2018001432 A1 CL2018001432 A1 CL 2018001432A1 CL 2018001432 A CL2018001432 A CL 2018001432A CL 2018001432 A CL2018001432 A CL 2018001432A CL 2018001432 A1 CL2018001432 A1 CL 2018001432A1
- Authority
- CL
- Chile
- Prior art keywords
- carbonitrile
- aminopropoxy
- ylamino
- pyrazol
- pyrazine
- Prior art date
Links
- SQQVRJAAUOKBIG-TYOUJGAFSA-N O.C([C@@H](O)C)(=O)O.NCCCOC1=C(C(=CC=C1)OC)C1=CC(=NN1)NC=1N=CC(=NC1)C#N Chemical compound O.C([C@@H](O)C)(=O)O.NCCCOC1=C(C(=CC=C1)OC)C1=CC(=NN1)NC=1N=CC(=NC1)C#N SQQVRJAAUOKBIG-TYOUJGAFSA-N 0.000 title 1
- JVTAAEKCZFNVCJ-REOHCLBHSA-M (S)-lactate Chemical compound C[C@H](O)C([O-])=O JVTAAEKCZFNVCJ-REOHCLBHSA-M 0.000 abstract 1
- 101000777293 Homo sapiens Serine/threonine-protein kinase Chk1 Proteins 0.000 abstract 1
- 206010028980 Neoplasm Diseases 0.000 abstract 1
- 102100031081 Serine/threonine-protein kinase Chk1 Human genes 0.000 abstract 1
- 201000011510 cancer Diseases 0.000 abstract 1
- 230000002401 inhibitory effect Effects 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/4965—Non-condensed pyrazines
- A61K31/497—Non-condensed pyrazines containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/13—Crystalline forms, e.g. polymorphs
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
LA PRESENTE INVENCIÓN SE REFIERE A MONOHIDRATO DE (S)-LACTATO DE 5-(5-(2-(3-AMINOPROPOXI)-6-METOXIFENIL)-1H-PIRAZOL-3-ILAMINO) PIRAZIN-2-CARBONITRILO QUE INHIBE LA CHK1/2 Y ES ÚTIL EN EL TRATAMIENTO DE CÁNCER.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201562263908P | 2015-12-07 | 2015-12-07 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CL2018001432A1 true CL2018001432A1 (es) | 2018-08-31 |
Family
ID=57570601
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CL2018001432A CL2018001432A1 (es) | 2015-12-07 | 2018-05-28 | 5- (5- (2- (3- aminopropoxi) -6-metoxifenilo) -1h-pirazol-3-ylamino) pirazina-2-carbonitrilo (s) -lactato monohidrato |
Country Status (26)
| Country | Link |
|---|---|
| US (1) | US10189818B2 (es) |
| EP (1) | EP3386975B1 (es) |
| JP (1) | JP6340485B2 (es) |
| KR (1) | KR20180079411A (es) |
| CN (1) | CN108349948B (es) |
| AR (1) | AR106772A1 (es) |
| AU (1) | AU2016367041B2 (es) |
| BR (1) | BR112018008398A2 (es) |
| CA (1) | CA3003914A1 (es) |
| CL (1) | CL2018001432A1 (es) |
| CO (1) | CO2018005676A2 (es) |
| EA (1) | EA201890953A1 (es) |
| EC (1) | ECSP18042905A (es) |
| ES (1) | ES2755740T3 (es) |
| HK (1) | HK1254207B (es) |
| IL (1) | IL258645A (es) |
| MX (1) | MX2018006899A (es) |
| NZ (1) | NZ741739A (es) |
| PE (1) | PE20181019A1 (es) |
| PH (1) | PH12018501213A1 (es) |
| SG (1) | SG11201803713WA (es) |
| SV (1) | SV2018005703A (es) |
| TN (1) | TN2018000125A1 (es) |
| TW (1) | TWI627168B (es) |
| WO (1) | WO2017100071A1 (es) |
| ZA (1) | ZA201802727B (es) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB202107932D0 (en) * | 2021-06-03 | 2021-07-21 | Sentinel Oncology Ltd | Preparation of a CHK1 Inhibitor Compound |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US8314108B2 (en) * | 2008-12-17 | 2012-11-20 | Eli Lilly And Company | 5-(5-(2-(3-aminopropoxy)-6-methoxyphenyl)-1H-pyrazol-3-ylamino)pyrazine-2-carbonitrile, pharmaceutically acceptable salts thereof, or solvate of salts |
| PA8850801A1 (es) * | 2008-12-17 | 2010-07-27 | Lilly Co Eli | Compuestos útiles para inhibir chk1 |
| TW201304778A (zh) * | 2010-11-16 | 2013-02-01 | Array Biopharma Inc | 檢查點激酶１抑制劑及ｗｅｅ１激酶抑制劑之組合 |
-
2016
- 2016-11-21 AR ARP160103564A patent/AR106772A1/es unknown
- 2016-11-21 TW TW105138012A patent/TWI627168B/zh active
- 2016-12-01 TN TNP/2018/000125A patent/TN2018000125A1/en unknown
- 2016-12-01 EP EP16813274.4A patent/EP3386975B1/en active Active
- 2016-12-01 ES ES16813274T patent/ES2755740T3/es active Active
- 2016-12-01 PE PE2018000982A patent/PE20181019A1/es unknown
- 2016-12-01 CN CN201680066323.8A patent/CN108349948B/zh active Active
- 2016-12-01 BR BR112018008398A patent/BR112018008398A2/pt not_active Application Discontinuation
- 2016-12-01 MX MX2018006899A patent/MX2018006899A/es unknown
- 2016-12-01 HK HK18113347.3A patent/HK1254207B/en unknown
- 2016-12-01 AU AU2016367041A patent/AU2016367041B2/en not_active Ceased
- 2016-12-01 US US15/513,185 patent/US10189818B2/en active Active
- 2016-12-01 SG SG11201803713WA patent/SG11201803713WA/en unknown
- 2016-12-01 NZ NZ741739A patent/NZ741739A/en not_active IP Right Cessation
- 2016-12-01 JP JP2017533543A patent/JP6340485B2/ja active Active
- 2016-12-01 KR KR1020187015617A patent/KR20180079411A/ko not_active Ceased
- 2016-12-01 CA CA3003914A patent/CA3003914A1/en not_active Abandoned
- 2016-12-01 WO PCT/US2016/064379 patent/WO2017100071A1/en not_active Ceased
- 2016-12-01 EA EA201890953A patent/EA201890953A1/ru unknown
-
2018
- 2018-04-11 IL IL258645A patent/IL258645A/en unknown
- 2018-04-24 ZA ZA2018/02727A patent/ZA201802727B/en unknown
- 2018-05-28 CL CL2018001432A patent/CL2018001432A1/es unknown
- 2018-05-29 CO CONC2018/0005676A patent/CO2018005676A2/es unknown
- 2018-06-06 SV SV2018005703A patent/SV2018005703A/es unknown
- 2018-06-06 EC ECIEPI201842905A patent/ECSP18042905A/es unknown
- 2018-06-07 PH PH12018501213A patent/PH12018501213A1/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| HK1254207B (en) | 2020-05-22 |
| KR20180079411A (ko) | 2018-07-10 |
| US20180230132A1 (en) | 2018-08-16 |
| EP3386975B1 (en) | 2019-09-25 |
| SG11201803713WA (en) | 2018-06-28 |
| AU2016367041A1 (en) | 2018-05-10 |
| AR106772A1 (es) | 2018-02-14 |
| PE20181019A1 (es) | 2018-06-26 |
| EA201890953A1 (ru) | 2018-11-30 |
| PH12018501213A1 (en) | 2019-02-04 |
| US10189818B2 (en) | 2019-01-29 |
| JP6340485B2 (ja) | 2018-06-06 |
| MX2018006899A (es) | 2018-09-06 |
| TW201728578A (zh) | 2017-08-16 |
| IL258645A (en) | 2018-06-28 |
| CN108349948B (zh) | 2021-02-23 |
| EP3386975A1 (en) | 2018-10-17 |
| ECSP18042905A (es) | 2018-06-30 |
| BR112018008398A2 (pt) | 2018-10-23 |
| TN2018000125A1 (en) | 2019-10-04 |
| SV2018005703A (es) | 2018-11-01 |
| AU2016367041B2 (en) | 2019-01-03 |
| WO2017100071A1 (en) | 2017-06-15 |
| ZA201802727B (en) | 2019-09-25 |
| TWI627168B (zh) | 2018-06-21 |
| CA3003914A1 (en) | 2017-06-15 |
| NZ741739A (en) | 2019-03-29 |
| CO2018005676A2 (es) | 2018-06-12 |
| CN108349948A (zh) | 2018-07-31 |
| JP2018501263A (ja) | 2018-01-18 |
| ES2755740T3 (es) | 2020-04-23 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JOP20190194A1 (ar) | مركبات نيوكليوتيدات ثنائية حلقية لعلاج السرطان | |
| EP3695666A4 (en) | DETECTION OF DRIVING ACTIONS THAT REDUCE THE RISK | |
| MX373103B (es) | Ciclopropilaminas como inhibidores de desmetilasa específica de lisina 1 (lsd1). | |
| IL292302B1 (en) | Use of glutamate modulating factors in cancer immunotherapy | |
| SV2016005279A (es) | Inhibidores de diacilglicerol aciltransferasa 2 | |
| MX377273B (es) | Ciclopropilamina como inhibidor de la desmetilasa 1 específica de lisinas (lsd1). | |
| EA201790649A1 (ru) | Бензилзамещенные индазолы в качестве ингибиторов bub 1 | |
| MX373045B (es) | Inhibidores de mdm2 y metodos terapeuticos que utilizan el mismo. | |
| PL3402888T3 (pl) | Środki i sposoby leczenia hbv | |
| PH12017501817B1 (en) | Heterocyclic compounds as lsd1 inhibitors | |
| TW201613860A (en) | Cyclopropylamines as LSD1 inhibitors | |
| MX2020004724A (es) | Composiciones de inh-c1 y métodos para la prevención y el tratamiento de trastornos asociados con la deficiencia del inhibidor de c1 esterasa. | |
| MX2020000386A (es) | Inhibidores heterociclicos de la cinasa atr. | |
| MX2017001352A (es) | Derivados de pirrolidinona como inhibidores de metionina aminopeptidasa 2 (metap-2). | |
| MX395231B (es) | Compuestos eficaces en el tratamiento de la hepatotoxicidad y enfermedades de hígado graso, y uso de los mismos. | |
| EP3556758A4 (en) | CDK4 / 6-INHIBITOR | |
| PL3582796T3 (pl) | Kompozycja do leczenia kaszlu | |
| ECSP18042905A (es) | Monohidrato de (s)-lactato de 5-(5-(2-(3-aminopropoxi)-6-metoxifenil)-1h-pirazol-3-ilamino)pirazin-2-carbonitrilo | |
| MX385652B (es) | Composicion heterofasica. | |
| MD3364975T2 (ro) | Combinație de trazodonă și gabapentină pentru tratamentul durerii | |
| MX2017011903A (es) | Composiciones para el tratamiento de enfermedades renales y/o hepaticas. | |
| ECSDI15020479S (es) | Bisagra | |
| TH1601000305A (th) | อนุพันธ์ไพร์โรลาไมด์ที่ถูกแทนที่ด้วยไกลออกซาไมด์ และการใช้สิ่งนั้นเป็นยาสำหรับการรักษาตับอักเสบ b | |
| JP1767725S (ja) | オフィスの内装 | |
| UA97245U (en) | Succinic acid application to strengthen the antihypoxic effect of thiotriazoline and quercetin |